User profiles for D. Cirstéa

D. Cristea

- Verified email at unitbv.ro - Cited by 2101

Dan Cristea

- Verified email at info.uaic.ro - Cited by 1887

[PDF][PDF] BalkaNet: Aims, methods, results and perspectives. a general overview

D Tufis, D Cristea, S Stamou - Romanian Journal of Information …, 2004 - researchgate.net
… relation (“no words are perfect synonyms” they say, and the evidence is that one cannot
replace one word with another in its synset without loosing or adding some fine details); d) its …

Clinical features of scleroderma patients with or without prior or current ischemic digital ulcers: post-hoc analysis of a nationwide multicenter cohort (ItinérAIR …

…, J Constans, D Cirstéa, D Farge-Bancel… - The Journal of …, 2009 - jrheum.org
Objective. Digital ulcers are the most frequent vascular manifestations of systemic sclerosis (SSc).
Clinical features of patients with prior or current digital ulcers have not been …

Properties of the thermally sprayed Al2O3–TiO2 coatings deposited on titanium substrate

…, G Marginean, I Hulka, VA Serban, D Cristea - International Journal of …, 2015 - Elsevier
Based on the fact that titanium and titanium alloys have poor fretting fatigue resistance and
poor tribological properties, it is necessary to apply some surface engineering methods in …

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

…, R Mazitschek, WC Ogier, D Cirstea… - Blood, The Journal …, 2012 - ashpublications.org
Histone deacetylase (HDAC) enzymatic activity has been linked to the transcription of DNA
in cancers including multiple myeloma (MM). Therefore, HDAC inhibitors used alone and in …

Improving light fastness of natural dyes on cotton yarn

D Cristea, G Vilarem - Dyes and pigments, 2006 - Elsevier
The objectives of this study were to evaluate the light fastness of selected natural dyes (madder,
weld and woad) and the effect of some commonly used antioxidants and UV absorbers …

Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma

…, M Fulciniti, G Gorgun, YT Tai, D Cirstea… - Blood, The Journal …, 2012 - ashpublications.org
Multiple myeloma (MM) cells are characterized by high protein synthesis resulting in chronic
endoplasmic reticulum (ER) stress, which is adaptively managed by the unfolded protein …

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

…, S Pozzi, L Santo, D Cirstea… - Proceedings of the …, 2010 - National Acad Sciences
Understanding the pathogenesis of cancer-related bone disease is crucial to the discovery
of new therapies. Here we identify activin A, a TGF-β family member, as a therapeutically …

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma

…, H Ikeda, G Bianchi, Y Hu, D Cirstea… - Blood, The Journal …, 2010 - ashpublications.org
Aurora-A is a mitotic kinase that regulates mitotic spindle formation and segregation. In
multiple myeloma (MM), high Aurora-A gene expression has been correlated with centrosome …

PI3K/p110δ is a novel therapeutic target in multiple myeloma

…, T Kiziltepe, L Santo, S Vallet, D Cristea… - Blood, The Journal …, 2010 - ashpublications.org
In this study, we demonstrate expression and examined the biologic sequelae of PI3K/p110δ
signaling in multiple myeloma (MM). Knockdown of p110δ by small interfering RNA caused …

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma

…, G Perrone, M Bandi, D Cirstea… - Blood, The Journal …, 2010 - ashpublications.org
The bone marrow (BM) microenvironment consists of extracellular-matrix and the cellular
compartment including immune cells. Multiple myeloma (MM) cell and BM accessory cell …